Paul Christian Baier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Christian Baier has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Dunja Hinze-Selch
3 shared publications- Manfred Hallschmid
Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen , Tübingen
2 shared publications Mareen Seeck-Hirschner
2 shared publicationsBirgit Gottwald
Department of Psychiatry and Psychotherapy, Christian-Albrechts University Kiel, Niemannsweg 147
1 shared publicationD. Hinze-Selch
1 shared publicationJ.B. Aldenhoff
1 shared publication
Latest Publications
- 20 March 2014
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 16 (3) , 16-17
Neue Erkenntnisse zur autoimmunen Genese von Narkolepsie mit Kataplexien
- 20 March 2014
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 16 (3) , 16-17
Neue Erkenntnisse zur autoimmunen Genese von Narkolepsie mit Kataplexien
- 1 December 2011
- Published by Elsevier in Sleep Medicine
- Vol. 12 (10) , 941-946
Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy
- 1 December 2011
- Published by Elsevier in Sleep Medicine
- Vol. 12 (10) , 941-946
Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy
- 30 September 2011
- Published by Elsevier in Sleep Medicine
- Vol. 12, S19
POSTPRANDIAL BLOOD GLUCOSE CONCENTRATIONS ARE INCREASED IN PATIENTS WITH NARCOLEPSY WITH CATAPLEXY AS COMPAREDWITH HEALTHY CONTROLS
- 30 September 2011
- Published by Elsevier in Sleep Medicine
- Vol. 12, S19
POSTPRANDIAL BLOOD GLUCOSE CONCENTRATIONS ARE INCREASED IN PATIENTS WITH NARCOLEPSY WITH CATAPLEXY AS COMPAREDWITH HEALTHY CONTROLS
- 1 March 2009
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 43 (6) , 585-591
A flow-cytometric method to investigate glutamate-receptor-sensitivity in whole blood platelets – Results from healthy controls and patients with schizophrenia
- 1 March 2009
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 43 (6) , 585-591
A flow-cytometric method to investigate glutamate-receptor-sensitivity in whole blood platelets – Results from healthy controls and patients with schizophrenia
- Open Access
- 21 August 2008
- Published by Oxford University Press (OUP) in Brain
- Vol. 131 (10) , 2734-2741
Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)
Until recently, olfactory dysfunction was an unknown feature of narcolepsy. Orexin A, also called hypocretin-1, is abnormally decreased or undetectable in the cerebrospinal fluid of narcoleptic patients with cataplexies. As hypothalamic orexin-containing neurons project throughout the entire olfactory pathway, from the olfactory mucosa to the olfactory cortex, disturbed orexinergic transmission may crucially be involved in impaired olfactory performance of narcolepsy patients. In our study we analysed the olfactory performance (threshold, discrimination, identification and sum score of these measurements, the TDI score) of narcoleptic patients with cataplexies (n = 10) and of age-, gender-, BMI- and smoker/non-smoker-matched healthy controls (n = 10). We then in a double-blind, randomized, placebo-controlled cross-over design applied orexin A intranasally to seven of the patients and measured 2-phenyl-ethyl alcohol (PEA) single-staircase odour detection thresholds. Compared to the controls, patients showed significantly lower scores for olfactory threshold (patients: median 8.0, range 4.0–10.5; controls: median 9.4, range 7.5–13.3; P < 0.05), discrimination (patients: median 12.5, range 10–15; controls: median 15.0, range 12–16; P < 0.005), identification (patients: median 13.0, range 10–16; controls: median 14.0, range 13–16; P < 0.05) and TDI score (patients: median 33.4, range 30–36; controls: median 38.4, range 35–43; P < 0.0001). In all patients, the PEA olfactory threshold score increased after administration of orexin A (median 11.5, range 6.5–13.25) compared to placebo (median 7.75, range 6.25–11.25; P < 0.05). Our results support the hypothesis that mild olfactory dysfunction is an intrinsic symptom of narcolepsy with cataplexies. The observation that intranasal orexin A restores olfactory function is in favour of this hypothesis. Furthermore, our data support that the pathophysiological mechanism underlying olfactory dysfunction in narcolepsy is the lack of CNS orexin.
- 21 August 2008
- Published by Oxford University Press (OUP) in Brain
- Vol. 131 (10) , 2734-2741
Open AccessOlfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1)
Until recently, olfactory dysfunction was an unknown feature of narcolepsy. Orexin A, also called hypocretin-1, is abnormally decreased or undetectable in the cerebrospinal fluid of narcoleptic patients with cataplexies. As hypothalamic orexin-containing neurons project throughout the entire olfactory pathway, from the olfactory mucosa to the olfactory cortex, disturbed orexinergic transmission may crucially be involved in impaired olfactory performance of narcolepsy patients. In our study we analysed the olfactory performance (threshold, discrimination, identification and sum score of these measurements, the TDI score) of narcoleptic patients with cataplexies (n = 10) and of age-, gender-, BMI- and smoker/non-smoker-matched healthy controls (n = 10). We then in a double-blind, randomized, placebo-controlled cross-over design applied orexin A intranasally to seven of the patients and measured 2-phenyl-ethyl alcohol (PEA) single-staircase odour detection thresholds. Compared to the controls, patients showed significantly lower scores for olfactory threshold (patients: median 8.0, range 4.0–10.5; controls: median 9.4, range 7.5–13.3; P < 0.05), discrimination (patients: median 12.5, range 10–15; controls: median 15.0, range 12–16; P < 0.005), identification (patients: median 13.0, range 10–16; controls: median 14.0, range 13–16; P < 0.05) and TDI score (patients: median 33.4, range 30–36; controls: median 38.4, range 35–43; P < 0.0001). In all patients, the PEA olfactory threshold score increased after administration of orexin A (median 11.5, range 6.5–13.25) compared to placebo (median 7.75, range 6.25–11.25; P < 0.05). Our results support the hypothesis that mild olfactory dysfunction is an intrinsic symptom of narcolepsy with cataplexies. The observation that intranasal orexin A restores olfactory function is in favour of this hypothesis. Furthermore, our data support that the pathophysiological mechanism underlying olfactory dysfunction in narcolepsy is the lack of CNS orexin.
- 1 January 2007
- Published by Wiley in Movement Disorders
- Vol. 22 (S18) , S459-S465
Animal studies in restless legs syndrome
Although restless legs syndrome (RLS) is a common disorder that has been studied thoroughly in the past decades, the underlying pathophysiology is still not fully understood. However, some attractive hypotheses on the pathogenesis of the disorder have been forwarded. Animal models are an important tool to verify hypotheses and to dissect out the details of pathophysiological mechanisms. Ideally they might serve the development of future treatment strategies. This review discusses the general and specific prerequisites necessary for the establishment of animal models for RLS and summarizes the approaches that have been made. © 2007 Movement Disorder Society
- 1 January 2007
- Published by Wiley in Movement Disorders
- Vol. 22 (S18) , S459-S465
Animal studies in restless legs syndrome
Although restless legs syndrome (RLS) is a common disorder that has been studied thoroughly in the past decades, the underlying pathophysiology is still not fully understood. However, some attractive hypotheses on the pathogenesis of the disorder have been forwarded. Animal models are an important tool to verify hypotheses and to dissect out the details of pathophysiological mechanisms. Ideally they might serve the development of future treatment strategies. This review discusses the general and specific prerequisites necessary for the establishment of animal models for RLS and summarizes the approaches that have been made. © 2007 Movement Disorder Society